GlassScriptPhysician profile
Li Tai Chuo
NPI 1841384211
$1,421.16
in general payments reported to CMS, 2019-2025
20 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $111 · 2021: $124 · 2022: $199 · 2023: $368 · 2024: $209 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $273.93 | 2019-2025 | Proclaim, Freestyle Libre 3 |
| Allergan, INC. | $210.55 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $187.83 | 2023-2024 | Hetlioz |
| Abbvie INC. | $159.16 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $155.39 | 2022-2025 | |
| Medtronic, INC. | $74.34 | 2021-2024 | Vanta Adaptivestim, Intellis Adaptivestim |
| Ultragenyx Pharmaceutical INC. | $63.78 | 2023-2024 | Crysvita |
| Glaxosmithkline, LLC. | $53.56 | 2021-2022 | |
| Novo Nordisk INC | $37.72 | 2022-2023 | Rybelsus, Ozempic |
| Amgen INC. | $34.67 | 2025 | Krystexxa, Otezla, Repatha |
| Inspire Medical Systems, INC. | $32.51 | 2025 | Inspire |
| Itamar Medical INC | $21.35 | 2023 | Watchpatone |
| Novartis Pharmaceuticals Corporation | $19.33 | 2021 | |
| Boston Scientific Corporation | $18.65 | 2021 | |
| Spinal Simplicity, LLC | $14.31 | 2025 | Ha Minuteman G3-R |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $13.81 | 2020 | |
| Horizon Therapeutics Plc | $13.68 | 2021 | |
| Astellas Pharma US INC | $13.64 | 2024 | Veozah |
| Gilead Sciences, INC. | $11.58 | 2019 | |
| Merck Sharp & Dohme LLC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Li Tai Chuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.